Construction, expression and characterization of human interferon α2b-(G4s)n-thymosin α1 fusion proteins in Pichia pastoris

World Journal of Gastroenterology

Volumn 11, Issue 17, 2005, Pages 2597-2602

  Yang, You Feng ^a   Yuan, Han Ying ^a   Liu, Nan Song ^a   Chen, Xiang Ling ^a   Gao, Bu Yu ^a   Lu, Hong ^a   Li, Yu Yang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Antiviral assay; E rosette assay; Fusion protein; Interferon 2b; Thymosin 1

Indexed keywords

2 DIETHYLAMINOETHANOL; ALPHA2B INTERFERON; DODECYL SULFATE SODIUM; HYBRID PROTEIN; RECOMBINANT ALPHA2B INTERFERON(G4S)THYMOSIN ALPHA1; RECOMBINANT PROTEIN; SUPERDEX 75; THYMOSIN ALPHA1; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANTIVIRAL ACTIVITY; ARTICLE; DNA SEQUENCE; DRUG TRANSFORMATION; EXPRESSION VECTOR; FUSION GENE; GEL FILTRATION; GENE THERAPY; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOLECULAR WEIGHT; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PICHIA PASTORIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROSETTE FORMING CELL;

EID: 18944399035     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i17.2597     Document Type: Article

References (28)

1. Di B, Martin P, Lisker-Melman M, Kassianides C, Korenman J, Bergasa NV, Baker B, Hoofnagle JH. Therapy of chronic delta hepatitis with interferon alfa-2b. J Hepatol 1990; 11 (Suppl 1): 151-154
2. Tamayo L, Ortiz DM, Orozco-Covarrubias L, Duran-McKinster C, Mora MA, Avila E, Teixeira F, Ruiz-Maldonado R. Therapeutic efficacy of interferon alfa-2b in infants with life-threatening giant hemangiomas. Arch Dermatol 1997; 133: 1567-1571
3. Romerio F, Zella D. MEK and ERK inhibitors enhance the anti-proliferative effect of interferon-alpha2b. FASEB J 2002; 16: 1680-1682
4. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm 2001; 58: 879-885
5. Billich A. Thymosin alpha1. SciClone Pharmaceuticals. Curr Opin Investig Drugs 2002; 3: 698-707
6. Rothstein KD, Munoz SJ. Interferon and other therapies for hepatitis B and hepatitis C infections. Clin Lab Med 1996; 16: 465-491
7. Molloy FJ, Azzouz M, Van T. Treatment of chronic hepatitis B and hepatitis C with interferon alfa-2b. Am Fam Physician 1996; 54: 1598-1605
8. Arase Y, Tsubota A, Suzuki Y, Suzuki F, Kobayashi M, Someya T, Akuta N, Hosaka T, Saitoh S, Ikeda K, Kobayashi M, Kumada H. A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients. Intern Med 2003; 42: 941-946
9. Saruc M, Yuceyar H, Kucukmetin N, Demir MA, Kandiloglu AR. Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey. Hepatogastroenterology 2002; 49: 798-802
10. Saruc M, Ozden N, Turkel N, Ayhan S, Hock LM, Tuzcuoglu I, Yuceyar H. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. J Pharm Sci 2003; 92: 1386-1395
11. Sherman KE, Sjogren M, Creager RL, Damiano MA, Freeman S, Lewey S, Davis D, Root S, Weber FL, Ishak KG, Goodman ZD. Combination therapy with thymosin alpha 1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial. Hepatology 1998; 27: 1128-1135
12. Moscarella S, Buzzelli G, Romanelli RG, Monti M, Giannini C, Careccia G, Marrocchi EM, Zignego AL. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results. Liver 1998; 18: 366-369
13. Rasi G, Pierimarchi P, Sinibaldi VP, Colella F, Garaci E. Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. Int Immunopharmacol 2003; 3: 1169-1176
14. Baron E, Narula S. From cloning to a commercial realization: human alpha interferon. Crit Rev Biotechnol 1990; 10: 179-190
15. Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, Nagabhushan TL, Walter MR. Zinc mediated dimer of human interferon-α2b revealed by X-ray crystallography. Structure 1996; 4: 1153-1163
16. Levy WP, Rubinstein M, Shively J, Del Valle U, Lai CY, Moschera J, Brink L, Gerber L, Stein S, Pestka S. Amino acid sequence of a human leukocyte interferon. Proc Natl Acad Sci USA 1981; 78: 6186-6190
17. Grottesi A, Sette M, Palamara T, Rotilio G, Garaci E, Paci M. The conformation of peptide thymosin alpha 1 in solution and in a membrane-like environment by circular dichroism and NMR spectroscopy. A possible model for its interaction with the lymphocyte membrane. Peptides 1998; 19: 1731-1738
18. Frankel AE, McCubrey JA, Miller MS, Delatte S, Ramage J, Kiser M, Kucera GL, Alexander RL, Beran M, Tagge EP, Kreitman RJ, Hogge DE. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia 2000; 14: 576-585
19. Thompson J, Stavrou S, Weetall M, Hexham JM, Digan ME, Wang Z, Woo JH, Yu Y, Mathias A, Liu YY, Ma S, Gordienko I, Lake P, Neville DM Jr. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. Protein Engineering 2001; 14: 1035-1041
20. Low TL, Thurman GB, McAdoo M, McClure J, Rossio JL, Naylor PH, Goldstein AL. The chemistry and biology of thymosin I. Isolation characterization, and biological activities of thymosin alphal and polypeptide betal from calf thymus. J Biol Chem 1979; 254: 981-986
21. Ahmed A, Wong DM, Thurman GB, Low TLK, Goldstein AL, Sharkis SJ, Goldschneider L. T-Lymphocyte maturation: Cell surface markers and immune unction induced by T-lymphocyte cell-free products and thymosin polypeptides. Ann NY Acad Sci 1979; 322: 81-94
22. Avdeeva ZI, Mazina. NM, Krylov OR, Olisova MO, Lukasheva TV, Medunitsyn NV. The immunomodulating action of interferon. The change in the rosette-forming activity of human blood lymphocytes under the influence of gamma-interferon and recombinant alpha 2-interferon. Vestn Dermatol Venerol 1990; 4: 16-19
23. Fuhlbrigge RC, Edwards BS, Borden EC. Effects of interferon alpha on the sheep erythrocyte "receptor" of human lymphocytes. J Interferon Res 1984; 4: 499-505
24. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002; 303: 540-548
25. Feng GS, Gray PW, Shepard HM, Taylor MW. Antiproliferative activity of a hybrid protein between interferon-gamma and tumor necrosis factor-beta. Science 1988; 241: 1501-1503
26. McCormick AL, Thomas MS, Heath AW. Immunization with an interferon-gamma-gpl20 fusion protein induces enhanced immune responses to human immunodeficiency virus gp120. J Infect Dis 2001; 184: 1423-1430
27. Kreitman RJ. Toxin-labeled monoclonal antibodies. Curr Pharm Biotechnol 2001; 2: 313-325
28. Slodowski O, Schöne B, Böhm J, Otto B. Carboxyterminal truncated rhu-IFN-gamma with a substitution of G1n133 or Ser132 to leucine leads to higher biological activity than in the wild type. Eur J Biochem 1991; 202: 1133-1140